• Japanese
  • Korean
  • Chinese
Cover Image

Cardiovascular Drug Delivery - technologies,markets and companies

Drug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and nutrients to all organs of the body. This report starts with an introduction to molecular cardiology and discusses its relationship to biotechnology and drug delivery systems.

Drug delivery to the cardiovascular system is approached at three levels: (1) routes of drug delivery; (2) formulations; and finally (3) applications to various diseases. Formulations for drug delivery to the cardiovascular system range from controlled release preparations to delivery of proteins and peptides. Devices for drug delivery to the cardiovascular system are also described.

Role of drug delivery in various cardiovascular disorders such as myocardial ischemia, hypertension and hypercholesterolemia is discussed. Controlled release systems are based on chronopharmacology, which deals with the effects of circadian biological rhythms on drug actions.A full chapter is devoted to drug-eluting stents as treatment for restenosis following stenting of coronary arteries.Fifteen companies are involved in drug-eluting stents.

Cell therapy approaches include attempts to reinitiate cardiomyocyte proliferation in the adult, conversion of fibroblasts to contractile myocytes, conversion of bone marrow stem cells into cardiomyocytes, and transplantation of myocytes or other cells into injured myocardium.

Gene therapy is not only a sophisticated method of drug delivery; it may at time need drug delivery devices such as catheters for transfer of genes to various parts of the cardiovascular system.

The cardiovascular drug delivery markets are estimated for the years 2012 to 2022 on the basis of epidemiology and total markets for cardiovascular therapeutics. Markets for drug-eluting stents are calculated separately. Role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified.

Table of Contents

0. Executive Summary

1. Cardiovascular Diseases

  • Introduction
  • History of cardiovascular drug delivery
  • Overview of cardiovascular disease
  • Molecular cardiology
  • Personalized cardiology
  • Important advances in cardiovascular therapeutics
  • Drug delivery, biotechnology and the cardiovascular system
  • Role of cardiovascular imaging in cardiovascular therapeutics
  • Chronopharmacotherapy of cardiovascular diseases

2. Methods for Drug Delivery to the Cardiovascular System

  • Introduction
  • Routes of drug delivery to the cardiovascular system
  • Local administration of drugs to the cardiovascular system
  • Formulations for drug delivery to the cardiovascular system
  • DDS to improve systemic delivery of cardiovascular drugs
  • Targeted drug delivery to the cardiovascular system
  • Devices for cardiovascular drug delivery
  • Drug delivery in the management of cardiovascular disease

3. Cell Therapy for Cardiovascular Disorders

  • Introduction
  • Methods of delivery of cells to the heart
  • Future directions for cell therapy of CVD

4. Gene Therapy for Cardiovascular Disorders

  • Introduction
  • Techniques of gene transfer to the cardiovascular system
  • Gene therapy for genetic cardiovascular disorders
  • Acquired cardiovascular diseases
  • Antisense therapy for cardiovascular disorders
  • RNAi for cardiovascular disorders
  • Future prospects of gene therapy of cardiovascular disorders
  • Companies involved in gene therapy of cardiovascular disorders

5. Drug-Eluting Stents

  • Introduction
  • Restenosis
  • Drug-eluting stents
  • Regulatory issues of DES
  • Future prospects for treatment of restenosis by DES

6. Markets for Cardiovascular Drug Delivery

  • Introduction
  • Epidemiology of cardiovascular disease
  • Cost of care of cardiovascular disorders
  • Cardiovascular markets according to important diseases
  • Markets for innovative technologies for cardiovascular disorders
  • Unmet needs for cardiovascular drug delivery
  • Role of DDS in developing cardiovascular markets

7. Companies involved in Cardiovascular Drug Delivery

  • Profiles of companies
  • Collaborations

8. References

Tables and Figures

Note: The Table of Contents has Been Edited for Brevity. For a Complete List of Tables and Figures Please Request a Free Sample.

Show More
Pricing
Get Notified
Email me when related reports are published